Allogeneic blood stem cell transplantation in advanced hematologic cancers

Area of Science:

• Hematology
• Oncology
• Transplant Medicine

Background:

• Allogeneic bone marrow transplantation (BMT) for advanced hematologic cancers carries high risks of morbidity and mortality.
• Graft-versus-host disease (GVHD) and regimen-related toxicity are significant challenges in BMT.

Purpose of the Study:

• To compare the short-term outcomes of allogeneic blood stem cell transplants (SCT) versus bone marrow transplants (BMT).
• To evaluate the efficacy and safety of different GVHD prophylaxis regimens in SCT.

Main Methods:

• A review of 74 adults with advanced hematologic cancer undergoing allogeneic transplantation from HLA-matched related donors.
• Three cohorts were analyzed: BMT with cyclosporine (CsA) and methotrexate (MTX), BMT with CsA and methylprednisolone (MP), and SCT with CsA and MP.
• All patients received filgrastim post-transplant.

Main Results:

• Blood stem cell recipients (Group 3) showed significantly faster neutrophil and platelet engraftment compared to bone marrow recipients (Group 1).
• Group 3 experienced less regimen-related toxicity, fewer early deaths, and earlier hospital discharge than other groups.
• While acute GVHD rates were similar, 180-day survival was significantly higher in the SCT group (Group 3) compared to the BMT with MP group (Group 2).

Conclusions:

• Allogeneic blood stem cell grafts offer substantial advantages over bone marrow grafts for patients with advanced hematologic cancers.
• SCT is associated with improved engraftment, reduced toxicity, and better survival outcomes compared to BMT.
• The use of CsA and MP for GVHD prophylaxis in SCT appears effective and safe.